Stockscreener 앱 받기
0.8581
3.37%
-0.0299
시간 외 거래:
.90
0.0419
+4.88%
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
0.60%
6.92%
자본화:
|
볼륨(24시간):